Pancreatic Cancer Surgery (Whipple) and Chemotherapy Cost Calculator
This calculator estimates the out-of-pocket cost of pancreatic cancer treatment in Korea and keeps the same pure calculation model as the Korean page for pancreaticoduodenectomy (the Whipple procedure), distal pancreatectomy, total pancreatectomy, robotic pancreatectomy, chemotherapy (FOLFIRINOX, gemcitabine plus nab-paclitaxel, gemcitabine alone), and concurrent chemoradiation (CCRT). Because pancreatic cancer is resectable in only about 10 to 20 percent of patients at diagnosis, chemotherapy is central to treatment, so the model treats it as a repeated per-cycle cost, on 2026 Korean rules.
Treatment options and covered fees
Pancreaticoduodenectomy (the Whipple procedure, PPPD) is the standard curative surgery for cancer of the pancreatic head, ampulla, or distal bile duct. It removes the pancreatic head with part of the duodenum, bile duct, and gallbladder and reconstructs the digestive tract, and it is the most complex gastrointestinal surgery, with a 2 to 3 week stay. The model uses KRW 22,000,000 as the covered base fee (covered total roughly KRW 24,000,000 with the ward fee), so the 5 percent special-case self-pay is about KRW 1,200,000.
Distal pancreatectomy (body or tail, with or without splenectomy) uses KRW 14,000,000 as the covered base fee and can be done laparoscopically or robotically. Total pancreatectomy uses KRW 24,000,000 and leaves the patient dependent on lifelong insulin and pancreatic enzyme replacement. Robotic pancreatectomy charges the robot surgery fee entirely out of pocket (KRW 8,000,000 to KRW 20,000,000, with KRW 12,000,000 as the average before regional and hospital adjustment), while the covered surgery base is zero.
- Vascular (portal or superior mesenteric vein) resection and reconstruction for borderline-resectable tumors adds KRW 3,000,000 as a covered add-on for surgical types.
- Covered ward fee is KRW 100,000 per inpatient day.
- Chemotherapy is billed per cycle and repeated; the model multiplies the per-cycle covered fee by the number of cycles.
- CCRT (concurrent chemoradiation) uses about KRW 9,000,000 covered for the outpatient course; proton or carbon-ion therapy is non-covered and far more expensive.
Chemotherapy is a repeated per-cycle cost
Because pancreatic cancer recurs often and is frequently unresectable, chemotherapy is the backbone of treatment and is repeated over many cycles. The model prices three regimens per cycle: FOLFIRINOX at about KRW 1,000,000 per 2-week cycle (adjuvant standard is up to 12 cycles for patients with good performance status), gemcitabine plus nab-paclitaxel (Abraxane) at about KRW 1,800,000 per 4-week cycle for metastatic first-line disease, and gemcitabine alone at about KRW 400,000 per cycle for older or frailer patients.
The real chemotherapy cost is therefore per-cycle fee multiplied by the number of cycles. All three regimens are covered by National Health Insurance, and cancer special-case registration lowers the covered copay to 5 percent per cycle. Without special-case registration, outpatient chemotherapy at a tertiary hospital can carry a copay as high as 60 percent, which is why registering first matters so much.
Cancer special-case copay and resectability
Ordinary inpatient treatment uses a 20 percent NHI copay. Pancreatic cancer special-case registration (cancer code V193) reduces the covered copay to 5 percent for 5 years when registered within 30 days of diagnosis, but it never applies to the non-covered robotic surgery fee, upper-grade room charges, pain-control injections, or proton and carbon-ion therapy. Inpatient days beyond day 31 may use 10 percent rather than 5 percent.
Resectability drives the treatment path and cost. Resectable disease is operated first; borderline-resectable disease (major vessel contact) usually starts with neoadjuvant FOLFIRINOX and then surgery with vascular resection and reconstruction; locally advanced unresectable disease uses chemotherapy or CCRT; and metastatic disease uses palliative chemotherapy. The resectability input is informational and does not change the fee, but it flags whether surgery alone is appropriate.
Robotic surgery, indemnity, and tax credit
Robotic pancreatectomy is mostly used for distal resection, and the robot fee is entirely self-pay. Because open surgery remains the standard for pancreatic cancer and the survival or complication advantage of robotic surgery is not clearly established, the calculator shows a robot-versus-covered-surgery comparison so patients can weigh the extra cost. The robot fee can also face private indemnity disputes, where the insurer argues the covered open or laparoscopic surgery was medically sufficient.
The estimate separates covered procedure fee, covered ward fee, robotic fee, room surcharge, pain-control injection, caregiver cost, private indemnity reimbursement, and the Korean medical expense tax credit (3 percent of salary threshold, 15 percent credit rate, with no KRW 7,000,000 cap for cancer patients as severe-disease patients under Income Tax Act Article 59-4). The annual copay ceiling (about KRW 870,000 to KRW 8,430,000 by income decile in 2026) can refund excess covered copay, and the public health center cancer cost support (up to KRW 3,000,000 per year) may apply.
How to read the result
Enter the treatment (Whipple, distal, total, robotic, chemotherapy, or CCRT), resectability, special-case registration, and either vascular resection (for surgery) or the chemotherapy regimen and cycle count. The result shows covered and non-covered self-pay, the chemotherapy cycle accumulation, the robot-versus-covered surgery comparison, the special-case 5 percent versus 20 percent comparison, and the final cost after private indemnity and tax credit.
This is a cost-planning estimate based on 2026 Korean rules, not medical advice. Public single-price tables for pancreatic surgery do not exist, so surgery figures are defensible market-estimate ranges that vary with hospital, stage, extent of surgery, complications, and drugs used. Confirm details with the treating multidisciplinary team, the insurer, and the hospital quote.
This calculator is based on Korean rules (2026 National Health Insurance cancer special-case program, Income Tax Act Article 59-4 medical expense tax credit, and market cost estimates for pancreatic cancer surgery and chemotherapy). Figures are planning estimates, not medical advice, an insurer decision, or a hospital quote.